Loading
NXC-201 CAR-T is an experimental CAR-T cell therapy from Nexcella in phase 2 trials, aimed at BCMA.
NXC-201 CAR-T (NXC-201, HBI0101) is a CAR-T cell therapy developed by Nexcella. Its target is BCMA. The sponsor states: Autologous T cells transduced ex vivo with an anti-BCMA CAR retroviral vector, provided fresh without cryopreservation. ClinicalTrials.gov describes the intervention as: NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryop. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06097832, plans to enrol 45 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov. The published efficacy data come from the Hadassah phase 1 in relapsed or refractory multiple myeloma (NCT04720313; Haematologica 2023): overall response 75 percent and complete response 50 percent in the first 20 patients, with only grade 1 to 2 cytokine release syndrome.
Autologous T cells transduced ex vivo with an anti-BCMA CAR retroviral vector, provided fresh without cryopreservation. Connects to BCMA.
1.NXC-201 CAR-T slips into a pocket on BCMA.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NXC-201 CAR-T" OR ABSTRACT:"NXC-201 CAR-T" OR TITLE:"NXC-201" OR ABSTRACT:"NXC-201" OR TITLE:"HBI0101" OR ABSTRACT:"HBI0101" OR TITLE:"HBI0101 CAR-T" OR ABSTRACT:"HBI0101 CAR-T") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NXC-201 CAR-T, not a curated reading list.
Shares BCMA, Multiple myeloma and the tag pipeline.
Shares BCMA, Multiple myeloma and the tag pipeline.
Shares BCMA, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.